EUVIMEDEUVIMED entdecken
Crossref

A Defect‐Engineered Nanozyme for Targeted NIR‐II Photothermal Immunotherapy of Cancer

Deblin Jana, Bing He, Yun Chen, Jiawei Liu, Yanli Zhao iD

Advanced Materials · 2024-03 · 36 (10)

DOI: 10.1002/adma.202206401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 11.11.2022. Verfasst von Deblin Jana und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, 21 Nanyang Link, Singapore, 637371, Singapore. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms. Die Arbeit wurde bisher 143-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Singapore Agency for Science, Technology and Research, Singapore National Research Foundation, National Research Foundation Singapore.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multienzyme‐mimicking redox nanozymes, curated by defect engineering, in synergy with immunotherapy offer promising prospects for safe and efficient cancer therapy. However, the spatiotemporally precise immune response often gets challenged by off‐target adverse effects and insufficient therapeutic response. Herein, a tumor cell membrane coated redox nanozyme (CMO‐R@4T1) is reported for combinational second near‐infrared window (NIR‐II) photothermal immunotherapy. CMO‐R@4T1 consists of a Cu‐doped MoO x (CMO) nanozyme as the core, which is cloaked with tumor‐cell‐derived fused membranes with immunostimulants immobilized in the membrane shell. In addition to the enhanced tumor accumulation, the nanozyme can cause oxidative damage to tumor cells by the production of reactive oxygen species and attenuation of the antioxidant mechanism. CMO‐R@4T1 also mediates a photothermal effect under NIR‐II photoirradiation to trigger tumor eradication and immunogenic cell death, where the liberated agonist elicits the immune activation. Such a controlled therapeutic paradigm potentiates systemic primary tumor ablation, inhibits cancer metastasis to distant tumor, and procures long‐term immunological memory. Thereby, this study takes advantage of defect engineering to illustrate a generic strategy to prepare cell‐membrane‐camouflaged nanozymes for targeted photo‐immunotherapy of cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsHumansCell MembraneAdjuvants, ImmunologicAntioxidantsCell Line, Tumor

Stichwörter der Autor:innen

cancer therapydefect engineeringimmunotherapynanozymessecond near-infrared window

Substanzen

Adjuvants, ImmunologicAntioxidants

Autor:innen und Institutionen

  • School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, 21 Nanyang Link, Singapore, 637371, Singapore.
  • Faculty of Materials Science and Chemistry, China University of Geosciences, Wuhan, 430074, P. R. China.

ORCID-Profile: Yanli Zhao

Förderung

  • Singapore Agency for Science, Technology and Research
  • Singapore National Research Foundation
  • National Research Foundation Singapore

Zitieren

APA

Jana, D., He, B., Chen, Y., Liu, J., & Zhao, Y. (2024). A Defect‐Engineered Nanozyme for Targeted NIR‐II Photothermal Immunotherapy of Cancer. Advanced Materials, 36(10). https://doi.org/10.1002/adma.202206401

Vancouver

Jana D, He B, Chen Y, Liu J, Zhao Y. A Defect‐Engineered Nanozyme for Targeted NIR‐II Photothermal Immunotherapy of Cancer. Advanced Materials. 2024;36(10). doi:10.1002/adma.202206401

BibTeX
@article{Jana2024,
  author = {Jana, Deblin and He, Bing and Chen, Yun and Liu, Jiawei and Zhao, Yanli},
  title = {A Defect‐Engineered Nanozyme for Targeted NIR‐II Photothermal Immunotherapy of Cancer},
  journal = {Advanced Materials},
  year = {2024},
  volume = {36},
  number = {10},
  doi = {10.1002/adma.202206401}
}
Kostenlos starten →